Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
Thompson
Philip A
PA
St. Vincent's Hospital, Melbourne, Australia.
Tam
Constantine S
CS
Thursky
Karin
K
Seymour
John F
JF
D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006509:Hepatitis B / Q000188:drug therapy / Q000209:etiology*; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000821:virology*; D011379:Prognosis; D000069283:Rituximab; D015996:Survival Rate; D014775:Virus Activation / Q000187:drug effects*
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab